Cenduit Launches New Professional Services Division
The Professional Services Division, provides hands-on experience for managing and enhancing Interactive Response Technology (IRT) systems.
Cenduit, a joint venture between Quintiles and Thermo Fisher Scientific, announced its new Professional Services Division, to provide hands-on experience for managing and enhancing Interactive Response Technology (IRT) systems.
Features of the new division include:
- Support with complex third-party system integrations and customizations
- Consulting for complex studies that require focused support
- Protocol-specific consulting (for example, needing an IVR set up where the patient will call in and report adverse events)
- Business analytics and reporting such as forecasting dashboard, enabling with effective decision support system for optimization.
Read the full release.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
